TNF and B-cell non-Hodgkin lymphoma: Rituximab is a chimeric mouse-human mAb that is specific for CD20 and is currently approved for the treatment of patients with non-Hodgkin's B-cell lymphoma and patients with rheumatoid arthritis who have exhibited an inadequate response to at least one TNF antagonist [34].